Strategies and practices in off-label marketing of pharmaceuticals: A retrospective analysis of whistleblower complaints

PLoS Medicine

Volumn 8, Issue 4, 2011, Pages 13-

  Kesselheim, Aaron S ^a,b   Mello, Michelle M ^c   Studdert, David M ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARSENIC TRIOXIDE; BOTULINUM TOXIN A; CICLOPIROXOLAMINE; CITALOPRAM; ESCITALOPRAM; FENTANYL CITRATE; GABAPENTIN; GAMMA1B INTERFERON; HUMAN GROWTH HORMONE; METFORMIN; MODAFINIL; NESIRITIDE; OLANZAPINE; OXCARBAZEPINE; OXYBATE SODIUM; PRAVASTATIN; PREGABALIN; QUETIAPINE; RAPAMYCIN; TIAGABINE; TOBRAMYCIN; TOPIRAMATE; VALDECOXIB; ZIPRASIDONE; DRUG;

CONSUMER ATTITUDE; CONTROL STRATEGY; DISEASE CLASSIFICATION; DRUG APPROVAL; DRUG CONTROL; DRUG DOSE; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; FRAUD; HUMAN; OFF LABEL DRUG USE; PHYSICIAN ATTITUDE; PHYSICIAN INCOME; PRESCRIPTION; RETROSPECTIVE STUDY; REVIEW; STRUCTURED QUESTIONNAIRE; WHISTLEBLOWING; ARTICLE; DRUG ADMINISTRATION; DRUG LABELING; LEGAL ASPECT; MARKETING; METHODOLOGY; STATISTICS; UNITED STATES;

DRUG ADMINISTRATION SCHEDULE; DRUG INDUSTRY; DRUG LABELING; HUMANS; MARKETING; OFF-LABEL USE; PHARMACEUTICAL PREPARATIONS; RETROSPECTIVE STUDIES; UNITED STATES; WHISTLEBLOWING;

EID: 79955451265     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1000431     Document Type: Review

References (55)

1. Kefauver-Harris Drug Amendments (1962) Public Law 87-781 (codified as amended at 21 U.S.C. § 352 (n)).
2. Fugh-Berman A, Melnick D, (2008) Off-label promotion, on-target sales. PLoS Med 5: e210 doi:10.1371/journal.pmed.0050210.
3. Psaty BM, Ray W, (2008) FDA guidance on off-label promotion and the state of the literature from sponsors. J Amer Med Assn 299: 1949-1951.
4. Henney JE, (2006) Safeguarding patient welfare: who's in charge? Ann Intern Med 145: 305-307.
5. Kesselheim AS, Avorn J, (2008) Pharmaceutical promotion to physicians and First Amendment rights. New Engl J Med 358: 1727-1732.
6. Kesselheim AS, Studdert DM, (2008) Whistleblower-initiated enforcement actions against health care fraud and abuse in the United States, 1996 to 2005. Ann Int Med 149: 342-349.
7. Almashat S, Preston C, Waterman T, Wolfe S, (2010) December 16 Rapidly increasing criminal and civil monetary penalties against the pharmaceutical industry: 1991 to 2010. Available: http://www.citizen.org/hrg1924. Accessed 10 February 2011.
8. Harris G, (2009) September 2 Pfizer pays $2.3 billion to settle marketing case. NY Times B4.
9. Department of Justice (2010) April 29 Two Johnson & Johnson subsidiaries to pay over $81 million to resolve allegations of off-label promotion of Topamax. Available: http://www.justice.gov/opa/pr/2010/April/10-civ-500.html. Accessed 10 February 2011.
10. Department of Justice (2010) April 27 Pharmaceutical giant AstraZeneca to pay $520 million for off-label drug marketing. Available: http://www.justice.gov/opa/pr/2010/April/10-civ-487.html. Accessed 10 February 2011.
11. Department of Justice (2010) May 4 Novartis vaccines & diagnostics to pay more than $72 million to resolve False Claims Act allegations concerning TOBI. Available: http://www.justice.gov/opa/pr/2010/May/10-civ-522.html. Accessed 10 February 2011.
12. Department of Justice (2010) September 15 Drug maker Forest pleads guilty; to pay more than $313 million to resolve criminal charges and False Claims Act allegations. Available: http://www.justice.gov/opa/pr/2010/September/10-civ-1028.html. Accessed 10 February 2011.
13. Department of Justice (2010) September 30 Novartis Pharmaceuticals Corp. to pay more than $420 million to resolve off-label promotion and kickback allegations. 30 Sept 2010. Available: http://www.justice.gov/opa/pr/2010/September/10-civ-1102.html. Accessed 10 February 2011.
14. Department of Justice (2010) September 1 Allergan agrees to plead guilty and pay $600 million to resolve allegations of off-label promotion of Botox®. Available: http://www.justice.gov/opa/pr/2010/September/10-civ-988.html. Accessed 10 February 2011.
15. Sandburg B, (2009) Health care fraud investigations bedevil Pharma industry: if you're not under investigation, it's only because you've recently settled. Pink Sheet 71: 21-24.
16. Hill KP, Ross JS, Egilman DS, Krumholz HM, (2008) The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med 149: 251-258.
17. Ross JS, Hill KP, Egilman DS, Krumholz HM, (2008) Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. J Amer Med Assn 299: 1800-1812.
18. Spielmans GI, (2009) The promotion of olanzapine in primary care: an examination of internal industry documents. Soc Sci Med 69: 14-20.
19. Steinman MA, Harper GM, Chren MM, Landefeld CS, Bero LA, (2007) Characteristics and impact of drug detailing for gabapentin. PLoS Med 4: e134 doi:10.1371/journal.pmed.0040134.
20. Steinman MA, Bero LA, Chren MM, Landefeld CS, (2006) Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med 145: 284-293.
21. Fugh-Berman A, Ahari S, (2007) Following the script: how drug reps make friends and influence doctors. PLoS Med 4: e150 doi:10.1371/journal.pmed.0040150.
22. Waxman HA, (2005) May 5 Memorandum re: marketing of Vioxx to physicians. Available: http://oversight.house.gov/documents/20050505114932-41272.pdf. Accessed 10 February 2011.
23. Kesselheim AS, Studdert DM, Mello MM, (2010) Experiences of whistle-blowers in major fraud litigation against pharmaceutical companies. New Engl J Med 362: 1832-1839.
24. Mello MM, Studdert DM, Brennan TA, (2009) Shifting terrain in the regulation of off-label promotion of pharmaceuticals. New Engl J Med 360: 1557-1566.
25. United States Department of Justice (2011) Office of Public Affairs Press Releases. Available: http://www.usdoj.gov/03press/03_1_1.html. Accessed 10 February 2011.
26. United States Judiciary (2011) Public Access to Court Electronic Records. Available: http://pacer.psc.uscourts.gov/. Accessed 10 February 2011.
27. Glaser BG, Strauss AL, (1967) The discovery of grounded theory: strategies for qualitative research New York Aldine De Gruyter Press.
28. Constas MA, (1992) Qualitative data analysis as a public event: the documentation of category development procedures. American Educational Research Journal 29: 253-266.
29. US ex rel. Franklin v. Parke-Davis, Division of Warner-Lambert Company (1996 August 13) Civil Action 1:96-CV-11651-PBS. Available: http://www.drugepi.org/downloads/downloads/WarnerLambert_Complaint1.pdf. Accessed 10 February 2011.
30. US ex rel. Collins,et al. v. Pfizer, Inc (2007 August 13) Civil Action 1:04-CV-11780-DPW. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint8.pdf. Accessed 10 February 2011.
31. US,et al. ex rel. Lauterbach v. Orphan Medical Inc., Jazz Pharmaceuticals Inc., and Dr. Peter Gleason (2006 February 17) Civil Action 05-CV-0387-SJF-KAM. Available: http://www.drugepi.org/downloads/downloads/OrphanMedical_Complaint1.pdf. Accessed 10 February 2011.
32. US,et al. ex rel. Boise v. Cephalon, Inc (2008 January 3) Civil Action 2:04-CV-04401-TON. Available: http://www.drugepi.org/downloads/downloads/Cephalon_Complaint4.pdf. Accessed 10 February 2011.
33. US ex rel. Kopchinski v. Pfizer, Inc. and Pharmacia Corp (2005 October 24) Civil Action 1:05-CV-12115-DPW. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint7.pdf. Accessed 10 February 2011.
34. US,et al. ex rel. Stromv. Scios, Inc. and Johnson & Johnson, Inc (2005 July 22) Civil Action 3:05-CV-03004-CRB. Available: http://www.drugepi.org/downloads/downloads/Scios_Complaint2.pdf. Accessed 10 February 2011.
35. US,et al. ex rel. Mulqueen,et al. v. Medicis Pharmaceutical Corp (2007 April 5) Civil Action 2:04-CV-02389-KHV-GLR. Available: http://www.drugepi.org/downloads/downloads/Medicis_Complaint1.pdf. Accessed 10 February 2011.
36. US,et al. ex rel. Gobble v. Forest Laboratories Inc., Forest Pharmaceuticals, Inc (2010 January 8) Civil Action 03-10395-NMG. Available: http://www.drugepi.org/downloads/downloads/Forest_Complaint1.pdf. Accessed 10 February 2011.
37. US,et al. ex rel. Copeland v. Novartis Pharmaceuticals Corp (2010 August 26) Civil Action 2:06-CV-01630-LDD. Available: http://www.drugepi.org/downloads/downloads/NovartisCase2_Complaint1.pdf. Accessed 10 February 2011.
38. US,et al. ex rel. Sandler and Paris v. Wyeth Pharmaceuticals, Inc. and Pfizer Inc (2010 May 24) Civil Action 2:05-CV-06609-JP. Available: http://www.drugepi.org/downloads/downloads/Wyeth_Complaint1.pdf. Accessed 10 February 2011.
39. US ex rel. Marchese v. Cell Therapeutics, Inc., et al (2007 August 24) Civil Action 2:06-CV-00168-MJP. Available: http://www.drugepi.org/downloads/downloads/CellTherapeutics_Complaint1.pdf. Accessed 10 February 2011.
40. US,et al. ex rel. Kruszewski v. Pfizer, Inc (2009 August 21) Civil Action 2:07-CV-04106-JCJ. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint5.pdf. Accessed 10 February 2011.
41. US,et al. ex rel. Wetta v. AstraZeneca Corporation (2008 August 1) Civil Action 2:04-CV-03479-BMS. Available: http://www.drugepi.org/downloads/downloads/AstraZeneca_Complaint1.pdf. Accessed 10 February 2011.
42. US ex rel. Gallagher v. Intermune, Inc (2004 July 9) Civil Action 04:CV-4323. Available: http://www.drugepi.org/downloads/downloads/Intermune_Complaint1.pdf. Accessed 10 February 2011.
43. US ex rel. Westlock v. Pfizer, Inc., et al (2008 August 1) Civil Action 1:08-CV-11318-DPW. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint2.pdf. Accessed 10 February 2011.
44. US ex rel. Liter v. Pfizer, Inc (2007 November 21) Civil Action 2:06-CV-00176-WOB. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint1.pdf. Accessed 10 February 2011.
45. US ex rel. Farber and Schildhauer v. Pfizer, Inc (2007 June 12) Civil Action 1:07-CV-10304-DPW. Available: http://www.drugepi.org/downloads/downloads/Pfizer_Complaint6.pdf. Accessed 10 February 2011.
46. US ex rel. Smith v. Scios, Inc., et al (2005 October 7) Civil Action 3:05-CV-04055-CRB. http://www.drugepi.org/downloads/downloads/Scios_Complaint1.pdf. Accessed 10 February 2011.
47. US ex rel. Lang and Rushin v. Allergan, Inc (2007 June 5) Civil Action 1:07-CV-01288-WSD. Available: http://www.drugepi.org/downloads/downloads/Allergan_Complaint2.pdf. Accessed 10 February 2011.
48. US,et al. ex rel. Garcia and Driscoll v. Serono, Inc (2003 October 6) Civil Action 03-CV-11892-GAO. Available: http://www.drugepi.org/downloads/downloads/Serono_Complaint1.pdf. Accessed 10 February 2011.
49. Drazen JM, de Leeuw PW, Laine C, Mulrow C, DeAngelis CD, et al. (2010) Toward more uniform conflict disclosures-the updated ICMJE conflict of interest reporting form. New Engl J Med 363: 188-189.
50. Physician Payments Sunshine Act (2009) H.R. 3590 § 6002.
51. PhRMA (2008) Code on interactions with health care professionals. Available: http://www.phrma.org/files/attachments/PhRMA%20Marketing%20Code%202008.pdf. Accessed 10 February 2011.
52. Pollack A, (2006 September 12) Stanford to ban drug makers' gifts to doctors, even pens. NY Times C2.
53. Edney A, (2010 October 15) Drugmaker CEOs may be targets for U.S. FDA in off-label cases, lawyer says. Bloomberg News. Available: http://www.bloomberg.com/news/2010-10-14/drugmaker-executives-may-become-targets-of-fda-for-off-label-promotions.html. Accessed 10 February 2011.
54. Wilson D, (2010 November 9) Ex-Glaxo executive is charged in drug fraud. NY Times B2.
55. Kindler J, (2010 March 17) Business must change to earn back the public's trust. Reuters. Available: http://blogs.reuters.com/great-debate/2010/03/17/business-must-change-to-earn-back-the-publics-trust/. Accessed 10 February 2011.